FDA Background for Colon Cancer Endpoints Workshop

First Page		Document Content
Prodrugs Organofluorides Oxaliplatin Chemotherapy regimens Capecitabine Irinotecan Adjuvant therapy FOLFOX Levamisole Chemistry Medicine Pharmacology		FDA Background for Colon Cancer Endpoints Workshop Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 395,76 KB Share Document on Facebook

	CRAB CTC: Phase I Study of Carfilzomib (C) and Irinotecan (I) in Relapsed Irinotecan-Sensitive Solid Tumors Susanne M. Arnold, MD1; Kari Chansky, PhD2; Markos Leggas, PhD1; Michael Thomson, MD3; John Hamm, MD4; Ra DocID: 1rySF - View Document
	MA En fase II-undersøgelse af irinotecan ugentligt til patienter med lokal avanceret eller metastatisk HER2positiv brystkræft og øget antal kopier af topoisomerase 1 (TOP1) genet Sponsor: DocID: 1rl7Y - View Document
	MA En fase II-undersøgelse af irinotecan ugentligt til patienter med lokal avanceret eller metastatisk HER2negativ brystkræft og øget antal kopier af topoisomerase 1(TOP1) genet. Sponsor: DocID: 1r6Cl - View Document
	fluorouracil pain relief, fluorouracil opthalmic solution fluorouracil generic alternative, fluorouracil package insert ic fluorouracil, wikipedia fluorouracil genital warts and fluorouracil. fluorouracil msds, fluoroura DocID: 1fzbO - View Document
	ZALTRAP® (ziv-aflibercept) DocID: 17zTi - View Document